Palvella Therapeutics, Inc. Operating Leases, Rent Expense
Palvella Therapeutics, Inc. (PVLA) reported Operating Leases, Rent Expense of $800.00 thousand for the 9-month period ending 2019-09-30, per its 10-Q filed 2019-11-12.
Discontinued › Expense Statement › Operating Expenses
us-gaap:LeaseAndRentalExpense · last filed 2020-03-13
- Palvella Therapeutics, Inc. operating leases, rent expense for the quarter ending 2019-03-31 was $11.50M.
- Palvella Therapeutics, Inc. operating leases, rent expense for the quarter ending 2015-12-31 was $18.40K.
- Palvella Therapeutics, Inc. operating leases, rent expense for the quarter ending 2015-09-30 was $0.00.
- Palvella Therapeutics, Inc. operating leases, rent expense for fiscal 2018 was $500.00K, a 0.00% change from fiscal 2017.
- Palvella Therapeutics, Inc. operating leases, rent expense for fiscal 2017 was $500.00K, a 0.00% change from fiscal 2016.
- Palvella Therapeutics, Inc. operating leases, rent expense for fiscal 2016 was $500.00K, a 2617.54% increase from fiscal 2015.
- Palvella Therapeutics, Inc. operating leases, rent expense for fiscal 2015 was $18.40K.
| Period end | Operating Leases, Rent Expense 3 month | Operating Leases, Rent Expense 6 month | Operating Leases, Rent Expense 9 month | Operating Leases, Rent Expense 12 month | Operating Leases, Rent Expense 12 month as first filed |
|---|---|---|---|---|---|
| 2019-09-30 | $800.00K 10-Q · filed 2019-11-12 | ||||
| 2019-03-31 | $11.50M 10-K · filed 2020-03-13 | ||||
| 2018-12-31 | $500.00K 10-K · filed 2020-03-13 | ||||
| 2017-12-31 | $500.00K 10-K · filed 2019-03-18 | ||||
| 2016-12-31 | $500.00K 10-K · filed 2018-03-15 | $200.00K 10-K · filed 2017-03-30 | |||
| 2015-12-31 | $18.40K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-30 | $18.40K derived: sum of 2 quarters · filed 2017-03-30 | $18.40K 10-K · filed 2017-03-30 | ||
| 2015-09-30 | $0.00 10-Q · filed 2015-11-13 | $0.00 10-Q · filed 2015-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |